Burning Rock Biotech Ltd
BNR34.000USD
+3.340+10.91%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
306.98MMarket Cap
LossP/E TTM
More Details of Burning Rock Biotech Ltd Company
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
Burning Rock Biotech Ltd Info
Ticker SymbolBNR
Company nameBurning Rock Biotech Ltd
IPO dateJun 12, 2020
CEOHan (Yusheng)
Number of employees674
Security typeDepository Receipt
Fiscal year-endJun 12
AddressNo. 5 Xingdao Ring Road North
CityGUANGZHOU
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code510005
Phone
Websitehttps://www.brbiotech.com/
Ticker SymbolBNR
IPO dateJun 12, 2020
CEOHan (Yusheng)
Company Executives of Burning Rock Biotech Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Yusheng Han
Mr. Yusheng Han
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Gang Lu
Mr. Gang Lu
Director
Director
--
--
Mr. Feng Deng
Mr. Feng Deng
Director
Director
--
--
Ms. Wendy Hayes, CPA
Ms. Wendy Hayes, CPA
Independent Director
Independent Director
--
--
Dr. Zhihong (Joe) Zhang, Ph.D.
Dr. Zhihong (Joe) Zhang, Ph.D.
Chief Technology Officer, Director
Chief Technology Officer, Director
--
--
Dr. Lisa (Licen) Xu
Dr. Lisa (Licen) Xu
Independent Director
Independent Director
--
--
Ms. Xiaozhi Hu
Ms. Xiaozhi Hu
Senior Director in Finance
Senior Director in Finance
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Yusheng Han
Mr. Yusheng Han
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Gang Lu
Mr. Gang Lu
Director
Director
--
--
Mr. Feng Deng
Mr. Feng Deng
Director
Director
--
--
Ms. Wendy Hayes, CPA
Ms. Wendy Hayes, CPA
Independent Director
Independent Director
--
--
Dr. Zhihong (Joe) Zhang, Ph.D.
Dr. Zhihong (Joe) Zhang, Ph.D.
Chief Technology Officer, Director
Chief Technology Officer, Director
--
--
Dr. Lisa (Licen) Xu
Dr. Lisa (Licen) Xu
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
China (Mainland)
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Feb 4
Updated: Wed, Feb 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Northern Light Venture Capital
11.68%
Kynam Capital Management LP
11.02%
Lyfe Capital
9.24%
CRCM L.P.
5.39%
China Merchants Bank Co Ltd
5.13%
Other
57.55%
Shareholders
Shareholders
Proportion
Northern Light Venture Capital
11.68%
Kynam Capital Management LP
11.02%
Lyfe Capital
9.24%
CRCM L.P.
5.39%
China Merchants Bank Co Ltd
5.13%
Other
57.55%
Shareholder Types
Shareholders
Proportion
Private Equity
20.91%
Hedge Fund
11.37%
Investment Advisor/Hedge Fund
6.30%
Bank and Trust
5.14%
Corporation
3.92%
Investment Advisor
0.85%
Research Firm
0.58%
Other
50.93%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
39
3.80M
46.56%
--
2025Q3
49
4.65M
47.27%
-5.46K
2025Q2
58
4.65M
51.33%
-759.34K
2025Q1
65
5.41M
53.38%
+589.94K
2024Q4
74
5.54M
50.70%
+348.38K
2024Q3
93
5.26M
57.60%
-7.02K
2024Q2
108
5.27M
61.36%
-5.69K
2024Q1
121
5.30M
64.27%
-181.25K
2023Q4
137
5.23M
65.24%
+745.66K
2023Q3
205
5.00M
74.63%
-61.48K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Northern Light Venture Capital
1.05M
11.68%
--
--
Mar 31, 2025
Kynam Capital Management LP
994.88K
11.02%
--
--
Sep 30, 2025
Lyfe Capital
833.84K
9.24%
--
--
Mar 31, 2025
CRCM L.P.
486.43K
5.39%
+264.85K
+119.53%
Dec 16, 2025
China Merchants Bank Co Ltd
462.99K
5.13%
--
--
Mar 31, 2025
Quantum Boundary Holdings Ltd
353.92K
3.92%
+350.62K
+10637.83%
Mar 31, 2025
Amova Asset Management Americas, Inc
45.55K
0.5%
+45.55K
--
Dec 31, 2024
Amova Asset Management Co., Ltd.
34.84K
0.39%
-9.09K
-20.68%
Sep 30, 2025
Renaissance Technologies LLC
31.72K
0.35%
--
--
Sep 30, 2025
BofA Global Research (US)
29.18K
0.32%
-100.00
-0.34%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Avantis Responsible Emerging Markets Equity ETF
0%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
0%
Avantis Responsible Emerging Markets Equity ETF
Proportion0%
DFA Dimensional Emerging Markets Core Equity 2 ETF
Proportion0%
SPDR S&P Emerging Markets Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
Apr 26, 2024
Merger
10→1
